Processa Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Digital Assets and Stablecoin Holdings

Digital Assets and Stablecoin Holdings	9 Months Ended
Sep. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]
Digital Assets and Stablecoin Holdings	Note 2 – Digital Assets and Stablecoin Holdings As of September 30, 2025, we held Digital Assets, consisting of USD-backed stablecoins, totaling $350,000, which are recorded as cash and cash equivalents on the consolidated balance sheet. These stablecoins are held in custodial wallets with third-party service providers and are redeemable on a one-to-one basis for U.S. dollars. We classify these stablecoins as cash equivalents under ASC 230, as they are fully collateralized by U.S. dollar reserves, readily convertible to known amounts of cash, and subject to insignificant risk of changes in value. Subsequent to September 30, 2025, we transferred an additional $500,000 to our third-party custodial wallet and we now hold a total of $850,000 in Digital Assets.

Digital Assets and Stablecoin Holdings

9 Months Ended

Sep. 30, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Note 2 – Digital Assets and Stablecoin Holdings

As of September 30, 2025, we held Digital Assets, consisting of USD-backed stablecoins, totaling $350,000, which are recorded as cash and cash equivalents on the consolidated balance sheet. These stablecoins are held in custodial wallets with third-party service providers and are redeemable on a one-to-one basis for U.S. dollars. We classify these stablecoins as cash equivalents under ASC 230, as they are fully collateralized by U.S. dollar reserves, readily convertible to known amounts of cash, and subject to insignificant risk of changes in value.

Subsequent to September 30, 2025, we transferred an additional $500,000 to our third-party custodial wallet and we now hold a total of $850,000 in Digital Assets.